Offline dengan aplikasi Player FM !
Diagnosing the drug R&D productivity decline with Dr Jack Scannell
Manage episode 415987216 series 3394247
In this episode, we discuss the problem of declining R&D efficiency with Dr. Jack Scannell, a scientist and entrepreneur who is well known for coining the term “Eroom’s law,” which highlights the decline in pharmaceutical research and development (R&D) productivity over several decades.
In this episode, Jack sheds light on the root causes of this decline, beginning with a critique of the poor quality of diagnosis surrounding the R&D productivity problem.
He also talks about the challenges in accurately measuring progress in drug research, highlighting the "measurement problem" in the drug industry. Jack suggests adopting a model akin to the "Stern Review” to improve the diagnosis of these challenges.
Jack also addresses topics such as the shift in the frequency of serendipitous drug discoveries, the Eroom’s law article, the entanglement of science, money and drug development and many more.
Feel free to navigate through any of the topics discussed in the Podcast using the timestamps below.
___
⭐ Timestamps:
0:00 Intro
01:40 Poor quality of diagnosis of the R&D productivity problem
04:01 The measurement problem
09:21 Chesterton’s fence of R&D
14:38 Science, Drug development, Money.
20:46 The role of Serendipity in drug discovery
26:34 Economics in the drug industry.
34:43 Implicit knowledge within Biotech
41:43 Eroom's Law paper
____
If you prefer listening to podcasts on audio apps, feel free to search for "The DeSci Podcast" on Spotify, Google Podcasts & Apple Podcasts. You'll also find all links to the podcast apps below.
If you want to join us on the show as a speaker or have guest ideas, please shoot us an mail at podcast@molecule.to
Special thanks to
Lea Degen: https://twitter.com/lealeata
Jack Scannell: https://twitter.com/JackScannell13
____
Let's connect:
Website: https://bit.ly/3d6nh2C
38 episode
Manage episode 415987216 series 3394247
In this episode, we discuss the problem of declining R&D efficiency with Dr. Jack Scannell, a scientist and entrepreneur who is well known for coining the term “Eroom’s law,” which highlights the decline in pharmaceutical research and development (R&D) productivity over several decades.
In this episode, Jack sheds light on the root causes of this decline, beginning with a critique of the poor quality of diagnosis surrounding the R&D productivity problem.
He also talks about the challenges in accurately measuring progress in drug research, highlighting the "measurement problem" in the drug industry. Jack suggests adopting a model akin to the "Stern Review” to improve the diagnosis of these challenges.
Jack also addresses topics such as the shift in the frequency of serendipitous drug discoveries, the Eroom’s law article, the entanglement of science, money and drug development and many more.
Feel free to navigate through any of the topics discussed in the Podcast using the timestamps below.
___
⭐ Timestamps:
0:00 Intro
01:40 Poor quality of diagnosis of the R&D productivity problem
04:01 The measurement problem
09:21 Chesterton’s fence of R&D
14:38 Science, Drug development, Money.
20:46 The role of Serendipity in drug discovery
26:34 Economics in the drug industry.
34:43 Implicit knowledge within Biotech
41:43 Eroom's Law paper
____
If you prefer listening to podcasts on audio apps, feel free to search for "The DeSci Podcast" on Spotify, Google Podcasts & Apple Podcasts. You'll also find all links to the podcast apps below.
If you want to join us on the show as a speaker or have guest ideas, please shoot us an mail at podcast@molecule.to
Special thanks to
Lea Degen: https://twitter.com/lealeata
Jack Scannell: https://twitter.com/JackScannell13
____
Let's connect:
Website: https://bit.ly/3d6nh2C
38 episode
Semua episode
×Selamat datang di Player FM!
Player FM memindai web untuk mencari podcast berkualitas tinggi untuk Anda nikmati saat ini. Ini adalah aplikasi podcast terbaik dan bekerja untuk Android, iPhone, dan web. Daftar untuk menyinkronkan langganan di seluruh perangkat.